Immunocore Holdings plc (IMCR)

NASDAQ: IMCR · IEX Real-Time Price · USD
35.90
+0.29 (0.81%)
Jun 29, 2022 4:00 PM EDT - Market closed
0.81%
Market Cap 1.58B
Revenue (ttm) 53.58M
Net Income (ttm) -156.07M
Shares Out 43.90M
EPS (ttm) -3.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 119,768
Open 35.85
Previous Close 35.61
Day's Range 34.92 - 37.37
52-Week Range 18.43 - 40.96
Beta n/a
Analysts Buy
Price Target 54.57 (+52.0%)
Earnings Date Aug 10, 2022

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 324
Stock Exchange NASDAQ
Ticker Symbol IMCR
Full Company Profile

Financial Performance

In 2021, IMCR's revenue was 26.52 million, a decrease of -11.93% compared to the previous year's 30.11 million. Losses were -131.52 million, 77.5% more than in 2020.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is 54.57, which is an increase of 52.01% from the latest price.

Price Target
$54.57
(52.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

5 Stocks With Recent Price Strength to Maximize Your Gains

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, UFCS, CWCO, HURN and FCN.

Other symbols: CWCOFCNHURNUFCS

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR ...

Other symbols: ALKSBLUGERN

Immunocore Appoints Siddharth Kaul to its Board of Directors

Immunocore Appoints Sidd h art h Kaul to its Board of Directors

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) ...

The UK Medicine s and Healthcare products Regulatory Agency ( MHRA ) , Australian Therapeutic Goods Administration (TGA) and Health Canada a pprove KIMMTRAK® ( tebentafusp ) for the treatment of unresec...

Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study

Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.

Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move Thi...

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, st...

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-a...

Immunocore announce s c linical t rial c ollaboration with Sanofi to evaluate Sanofi's product candidate SAR 444 245 , non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and Ne...

The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel , May 23, 2022 /PRNewswire/ ...

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

Immunocore to present at the 21st Annual Needham Healthcare Conference

Immunocore to present at the 21 st Annual Needham Healthcare Conference

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.

Other symbols: LEGN

3 CEOs to Invest In

Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.

Other symbols: AXSMGSK

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves to Buy: Rationale Behind the Upgrade

Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near...

Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move Thi...

The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metri...

Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference

Immunocore to present at Oppenheimer's 32 nd Annual Healthcare Conference

Immunocore to present at the SVB Leerink Global Healthcare Conference

Immunocore to present at the SVB Leerink Global Healthcare Conference

FDA Approves First T Cell Receptor Therapy From Immunocore For Eye Cancer

The FDA has approved Immunocore Holdings plc (tebentafusp-tebn) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uve...

Immunocore announces FDA approval of KIMMTRAK ® ( tebentafusp- tebn ) for the treatment of unresectable or metastatic uveal melanoma